1. 270 Large single-site institution experience of testing for somatic and germline concordance BRCA1/2 pathogenic mutations in ovarian cancer patients eligible for PARP inhibitors therapy. (18th September 2019) Authors: Akaev, I; Chau, C; Dabab, N; Rahimi, S; Gardner, F; Yeoh, CC Journal: International journal of gynecological cancer Issue: Volume 29(2019)Supplement 3 Page Start: A114 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗